Download Files:
Besifovir
$170 – $1,120
Products Details
Product Description
– Besifovir (LB80331), a parent agent converted by LB80380 (HY-19447A), further metabolizes to its active form, LB80317 (HY-106235). Besifovir is an orally active, novel antiviral agent against hepatitis B virus (HBV)[1][2].
Web ID
– HY-19447
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C10H14N5O4P
References
– [1]Jung JA, et al. Pharmacokinetic comparison of the maleate and free base formulations of LB80380, a novel nucleotide analog, in healthy male volunteers. Int J Clin Pharmacol Ther. 2012 Sep;50(9):657-64.|[2]Yuen MF, et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther. 2006;11(8):977-83.|[3]Lung-Yi Mak, et al. Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):101-106.
CAS Number
– 441785-25-7
Molecular Weight
– 299.22
Compound Purity
– 98.0
SMILES
– NC1=NC=C2N=CN(CC3(OCP(O)(O)=O)CC3)C2=N1
Clinical Information
– Launched
Research Area
– Infection
Solubility
– DMSO : 250 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL
Target
– HBV
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
